Impact of Multiple Negative Charges on Blood Clearance and Biodistribution Characteristics of 99mTc-Labeled Dimeric Cyclic RGD Peptides

Bioconjugate Chemistry

Volumn 25, Issue 9, 2014, Pages 1720-1729

  Yang, Yong ^a   Ji, Shundong ^a   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BLOOD; PEPTIDES; RADIATION; RADIOACTIVITY;

ATHYMIC; BIODISTRIBUTIONS; INTEGRINS; NEGATIVE CHARGE; NUDE MICE; PROPERTY; RADIOACTIVITY LEVEL; RGD PEPTIDE; SPECT/CT; TUMOR UPTAKE;

TUMORS;

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; DIISOPROPYLETHYLAMINE; ECHISTATIN; ETHYLAMINE; IODINE 125; TECHNETIUM 99M; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; GLIOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN BINDING; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; WHOLE CELL; ANIMAL; BLOOD; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DIMERIZATION; FEMALE; HUMAN; KINETICS; METABOLISM; RADIOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; DIMERIZATION; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; KINETICS; MICE; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; RADIOCHEMISTRY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84921465250     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500309r     Document Type: Article

References (63)

1. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1, 27 - 31
2. 5 integrin expression in glioma periphery Neurosurgery 49, 380 - 389
3. Hwang, R. and Varner, J. (2004) The role of integrins in tumor angiogenesis Hematol. Oncol. Clin. North Am. 18, 991 - 1006
4. Jin, H. and Varner, J. (2004) Integrins: roles in cancer development and as treatment targets Br. J. Cancer 90, 561 - 565
5. Zitzmann, S., Ehemann, V., and Schwab, M. (2002) Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo Cancer Res. 62, 5139 - 5143
6. 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 61, 1781 - 1785
7. Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation Chem.-Eur. J. 9, 2717 - 2725
8. Poethko, T., Schottelius, M., Herz, M., Haubner, R., Henriksen, G., Schwaiger, M., Wester, H. j., Thumshirn, G., and Kessler, H. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation Radiochimica. Acta 92, 317 - 327
9. 18F-labeled RGD and octreotide analogs J. Nucl. Med. 45, 892 - 902
10. 18F] Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates Bioconjugate Chem. 15, 61 - 69
11. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis Nucl. Med. Biol. 31, 179 - 189
12. 125I-labeled RGD peptide are improved by PEGylation Nucl. Med. Biol. 31, 11 - 19
13. 3-targeted imaging of lung cancer Neoplasia 7, 271 - 279
14. 64Cu-labeled tetrameric RGD peptide J. Nucl. Med. 46, 1707 - 1718
15. 3 integrin expression J. Nucl. Med. 48, 1162 - 1171
16. 18F-FPRGD4) J. Nucl. Med. 48, 1536 - 1544
17. 3 PET imaging Eur. J. Nucl. Med. Mol. Imaging 36, 947 - 957
18. 18F-aryltrifluoroborate conjugates for functional imaging Am. J. Nucl. Med. Mol. Imaging 3, 44 - 56
19. 4 linkers Eur. J. Nucl. Med. Mol. Imaging 36, 1296 - 1307
20. 111In-labeled RGD Peptide Nucl. Med. Biol. 34, 29 - 35
21. 3 integrin by multimerization of RGD peptides Eur. J. Nucl. Med. Mol. Imaging 34, 267 - 273
22. 5 determined from whole-body PET/CT in monkeys and humans J. Nucl. Med. 53, 787 - 795
23. 3 integrin-binding radiotracer J. Label Compd. Radiopharm. 55, 423 - 426
24. 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process Nucl. Med. Biol. 39, 777 - 784
25. 99mTc-labeled RGD peptide as an angiogenesis imaging agent Nucl. Med. Biol. 40, 262 - 272
26. Haubner, R. and Wester, H. J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies Curr. Pharm. Des. 10, 1439 - 1455
27. Meyer, A., Aurenheimer, J., Modlinger, A., and Kessler, H. (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting Curr. Pharm. Des. 12, 2723 - 2747
28. 3-targeted radiotracers: maximizing binding affinity via bivalency Bioconjugate Chem. 20, 2199 - 2213
29. Dijkgraaf, I. and Boerman, O. C. (2010) Molecular imaging of angiogenesis with SPECT Eur. J. Nucl. Med. Mol. Imaging 37 (Suppl 1) S104 - S113
30. 3-targeted PET tracers Curr. Med. Chem. 19, 3301 - 3309
31. Liu, S. and Edwards, D. S. (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals Bioconjugate Chem. 12, 7 - 34
32. Liu, S. (2004) The role of coordination chemistry in development of target-specific radiopharmaceuticals Chem. Soc. Rev. 33, 445 - 461
33. Liu, S. (2008) Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides Adv. Drug Delivery Rev. 60, 1347 - 1370
34. 3 receptor antagonists for tumor imaging and radiotherapy Cancer Biother. Radiopharm. 18, 627 - 641
35. 3 receptor antagonist: different but biologically equivalent Bioconjugate Chem. 15, 235 - 241
36. Harris, T. D., Cheesman, E., Harris, A. R., Sachleben, R., Edwards, D. S., Liu, S., Bartis, J., Ellars, C., Onthank, D., Yalamanchili, P., Heminway, S., Silva, P., Robinson, S., Lazewatsky, J., Rajopadhye, M., and Barrett, J. (2007) Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents Bioconjugate Chem. 18, 1266 - 1279
37. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents Bioconjugate Chem. 17, 1294 - 1313
38. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers J. Med. Chem. 51, 7980 - 7990
39. 4 linkers Mol. Pharmaceutics 6, 231 - 245
40. 3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics Eur. J. Nucl. Med. Mol. Imaging 36, 1874 - 1884
41. 4 linkers Bioconjugate Chem. 20, 750 - 759
42. 111In-labeled cyclic RGD peptides: tetrameric not tetravalent Bioconjugate Chem. 21, 969 - 978
43. 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics Bioconjugate Chem. 20, 1559 - 1568
44. 111In-labeled cyclic RGD peptides: effects of peptide and linker multiplicity on their tumor uptake, excretion kinetics and metabolic stability Theranostics 1, 322 - 340
45. 111In-labeled cyclic peptide RGD dimers Amino Acids 41, 1059 - 1070
46. 3 expression Mol. Imaging 10, 386 - 397
47. 99mTc chelates on biological properties Bioconjugate Chem. 23, 586 - 595
48. 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging Mol. Pharmacol. 10, 3304 - 3314
49. 3 expression Nuklearmedizin 43, 26 - 32
50. 2 scintigraphy Eur. J. Nucl. Med. Mol. Imaging 38, 2145 - 2152
51. 2 for integrin receptor imaging of lung cancer: a multicenter study J. Nucl. Med. 53, 716 - 722
52. 2 J. Nucl. Med. 53, 1872 - 1877
53. Carter, D. C. and Ho, J. X. (1994) Structure of serum albumin Adv. Protein Chem. 45, 153 - 203
54. Sugio, S., Kashima, A., Mochizuki, S., Noda, M., and Kobayashi, K. (1999) Crystal structure of human serum albumin at 2.5 Å resolution Protein Eng. 12, 439 - 446
55. He, X. M. and Carter, D. C. (1992) Atomic structure and chemistry of human serum albumin Nature 358, 209 - 215
56. Moriggi, L., Yaseen, M. A., Helm, L., and Caravan, P. (2012) Serum albumin targeted, pH-dependent magnetic resonance relaxation agents Chem.-Eur. J. 18, 3675 - 3686
57. Boros, E. and Caravan, P. (2013) Structure-relaxivity relationships of serum albumin targeted MRI probes based on a single amino acid Gd complex J. Med. Chem. 56, 1782 - 1786
58. Pierre, V. C., Allen, M. J., and Caravan, P. (2014) Contrast agents for MRI: 30+ years and where are we going? J. Biol. Inorg. Chem. 19, 127 - 131
59. 99mTc-labeled radiopharmaceuticals Bioconjugate Chem. 10, 808 - 814
60. 3 Mol. Imaging 12, 39 - 48
61. 2 Theranostics 2, 577 - 588
62. 2 therapy Theranostics 3, 816 - 830
63. 2 J. Pharmacol. Exp. Ther. 346, 251 - 258